Compare Ambarella Inc (AMBA) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ambarella Inc vs IDEXX Laboratories, Inc. — how do they compare? Ambarella Inc trades at $83.35 (market cap $3.64B), while IDEXX Laboratories, Inc. trades at $574.09 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 12.7× Ambarella Inc's market cap, and Ambarella Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| AMBA | IDXX | |
|---|---|---|
Market Cap | $3.64B | $46.22B |
Sector | Technology | Health |
52-Week High | $95.51 | $766.68 |
52-Week Low | $48.65 | $526.44 |
Enterprise Value | $3.37B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $83.98, up 2.36% with strong technical momentum and bullish analyst sentiment. The stock shows positive earnings momentum with three consecutive quarterly beats, though the company remains unprofitable with a -17.18% net margin. Recent news of potential acquisition talks with NXP Semiconductors and strong positioning in edge AI markets provide catalysts for growth.
The outlook remains positive with a $108.67 consensus price target representing 29% upside potential. Key risks include ongoing profitability challenges, competitive pressures in semiconductor markets, and execution risks in transitioning to AI-focused products. The company's pivot to edge AI and automotive applications offers significant growth opportunities if successfully executed.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ambarella Inc
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
